Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease



Status:Recruiting
Conditions:Blood Cancer, Lymphoma, Leukemia
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Start Date:August 2007

Use our guide to learn which trials are right for you!

A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin'd Lymphoma (NHL)

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming
normal cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not
responded to chemotherapy, surgery or radiation therapy.

PURPOSE: Phase 1 dose escalation study to determine the maximum tolerated dose of CAT-8015
immunotoxin in treating patients who have Non-Hodgkin's lymphoma and do not respond to
treatment.


INCLUSION CRITERIA:

DISEASE CHARACTERISTICS:

- Confirmed diagnosis of B-cell non-Hodgkin's lymphoma

- Measurable disease

- Evidence of CD22-positive malignancy by the following criteria,

- > 30% of malignant cells from a disease site CD22+ by FACS analysis or,

- > 15% of malignant cells from a disease site must react with anti-CD22 by
immunohistochemistry

- Patients with indolent subtypes of CD22+ B-cell non-Hodgkin's lymphoma, including,
but not limited to mantle cell lymphoma, follicular lymphoma and Waldenström's
macroglobulinemia, are eligible if stage III-IV.

- Patients must have failed at least two or more courses of prior standard chemotherapy
and/or biologic therapy (e.g. Rituxan). Patients with progressive mantle cell
lymphoma may be eligible if they have failed one prior standard therapeutic regimen.

PATIENTS CHARACTERISTICS

Performance Status

- ECOG 0-2

Life Expectancy

- Life expectancy of less than 6 months, as assessed by the principal investigator

Other

- Patients with other cancers who meet eligibility criteria and have less than 5 years
of disease free survival will be considered on a case-by-case basis

- Must be able to understand and sign informed consent

- Female and male patients must agree to use an approved method of contraception during
the study

Exclusion Criteria:

- History of bone marrow transplant

- Documented and ongoing central nervous system involvement with their malignant
disease (history of CNS involvement is not an exclusion criterion)

- Pregnant or breast-feeding females

- Patients whose plasma contains either a significant level of antibody to CAT-8015 as
measured by ELISA, or antibody that neutralizes the binding of CAT-8015 to CD22 as
measured by a competition ELISA.

- HIV positive serology (due to increased risk of severe infection and unknown
interaction of CAT-8015 with antiretroviral drugs)

- Hepatitis B surface antigen positive

- Uncontrolled, symptomatic, intercurrent illness including but not limited to:
infections requiring systemic antibiotics, congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would
limit compliance with study requirements

Hepatic function: serum transaminases (either ALT or AST) or bilirubin

- ≥ Grade 2, unless bilirubin is due to Gilbert's disease

Renal function: Serum creatinine clearance ≤ 60mL/min as estimated by Cockroft-Gault
formula

Hematologic function:

- The ANC < 1000/cmm, or platelet count <50,000/cmm, if these cytopenias are not judged
by the investigator to be due to underlying disease (i.e. potentially reversible with
anti-neoplastic therapy).

- A patient will not be excluded because of pancytopenia ≥ Grade 3, or erythropoietin
dependence, if it is due to disease, based on the results of bone marrow studies

- Baseline coagulopathy > Grade 3 unless due to anticoagulant therapy.

Pulmonary function:

- Patients with < 50% of predicted forced expiratory volume (FEV1) or <50% of predicted
diffusing capacity for carbon monoxide (DLCO), corrected for hemoglobin concentration
and alveolar volume. Note: Patient with no prior history of pulmonary illness are not
required to have PFTs. FEV1 will be assessed after bronchodilator therapy.

Recent prior therapy:

- Cytotoxic chemotherapy, corticosteroids (except stable doses of prednisone), whole
body electron beam radiation therapy, hormonal, biologic or other standard or any
investigational therapy of the malignancy for 3 weeks prior to entry into the trial

- Less than or equal < 3 months prior monoclonal antibody therapy (i.e. rituximab)

- Patients who are receiving or have received radiation therapy less than 3 weeks prior
to study entry will be not be excluded providing the volume of bone marrow treated is
less than 10% and also the patient has measurable disease outside the radiation port

- Any history of prior pseudomonas-exotoxin immunotoxin (PE) administration.
We found this trial at
2
sites
Beverly Hills, California 90211
21
mi
from 91732
Beverly Hills, CA
Click here to add this to my saved trials
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials